- Comparison of Helicobacter pylori Eradication Rate in Patients with Non-ulcer Dyspepsia and Peptic Ulcer Diseases according to Proton Pump Inhibitors
-
Hong EJ, Park DI, Oh SJ, Song MJ, Choi WH, Hong CH, Park JH, Kim HJ, Cho YK, Shon CI, Jeon WK, Kim BI
- KMID: 783038
- Korean J Gastroenterol.
- 2008 Aug;52(2):80-85.
BACKGROUND/AIMS: Conflicting results have been reported whether patients with non-ulcer dyspepsia (NUD) respond differently to Helicobacter pylori (H. pylori) eradication treatment compared with patients with peptic ulcer diseases (PUD). The... -
- CITED
-
- Close
- SHARE
-
- Close
- A Prospective Study on Rabeprazole-based Triple Therapy for Helicobacter pylori Eradication in Patients with Peptic Ulcer
-
Choi BK, Yang SY, Park ET, Jang YS, Lee YJ, Lee SH, Seol SY, Chung JM
- KMID: 772530
- Korean J Gastroenterol.
- 2003 Aug;42(2):102-107.
BACKGROUND/AIMS: Rabeprazole sodium is a potent proton pump inhibitor. We assessed the efficacy, safety and compliance of one-week triple therapy including rabeprazole with amoxicillin and clarithromycin for eradication of... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Triple Therapy with Rabeprazole for Helicobacter pylori Infection in relation to CYP2C19 Genotype
-
Lee SB, Park SJ, Ryu JK, Lee JK, Kim HJ, Bae JS, Jung HS, Park SM
- KMID: 1066037
- Korean J Gastroenterol.
- 2003 Dec;42(6):468-475.
BACKGROUND/AIMS: Genetic polymorphism of cytochrome P450 CYP2C19 influences the efficacy of proton pump inhibitor (PPI) in Helicobacter pylori (H. pylori) eradication therapy. We investigated the difference in the cure... -
- CITED
-
- Close
- SHARE
-
- Close
